Targeted therapies for cancer have been developed, and these are based on drugs that have significant metabolic consequences, which are associated with a significant increase in plasma triglycerides by reducing the activity of the lipoprotein lipase, in charge of the catabolism of triglyceride-rich lipoproteins and associated with a high incidence of hyperglycemia or hypoglycemia [36]. The gene discussed is LPL; the disease is Hypoglycemia.